Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis

NCT00770913 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

337

Enrollment

INDUSTRY

Sponsor class

Conditions

Refractory Reflux Esophagitis

Interventions

DRUG: E3810
DRUG: E3810
DRUG: E3810

Sponsor

Eisai Co., Ltd.